Enzolytics

Candidate: Anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 Types: Fully human monoclonal antibodies targeting immutable sites confirmed as 98.71% to 99.29% conserved over the entirety of […]

Enzolytics

Candidate: Anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 Types: Fully human monoclonal antibodies targeting immutable sites confirmed as 98.71% to 99.29% conserved over the entirety of […]